Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
View Patent ↗Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
1. A method of treating metastasis or inhibiting metastasis in a subject having anaplastic thyroid carcinoma or large lung cell cancer or osteosarcoma comprising administering to the subject an amount of an inhibitor of CEP192 effective to treat metastasis or inhibit metastasis of anaplastic thyroid carcinoma or large lung cell cancer or osteosarcoma, respectively, wherein the inhibitor of CEP192 is a siRNA directed to CEP192 or a shRNA directed to CEP192.
2. A method of treating fibrosis or scarring, or inhibiting fibrosis or scarring, in a subject comprising administering to the subject an amount of an inhibitor of CEP192 effective to treat fibrosis or scarring, or inhibit fibrosis or scarring, wherein the inhibitor of CEP192 is a siRNA directed to CEP192 or a shRNA directed to CEP192.
3. A method of treating pain associated with wound healing in a subject having a wound comprising administering to the subject an amount of an inhibitor of CEP192 effective to treat pain associated with wound healing, wherein the inhibitor of CEP192 is a siRNA directed to CEP192 or a shRNA directed to CEP192.
4. The method of claim 1 , wherein the CEP192 is a human CEP192.
5. The method of claim 1 , wherein the siRNA is administered.
6. The method of claim 1 , wherein the shRNA is administered.
7. The method of claim 5 , wherein the siRNA is administered as a composition comprising the siRNA associated with a nanoparticle.
8. The method of claim 6 , wherein the shRNA is administered as a composition comprising the shRNA encapsulated with a nanoparticle.
9. The method of claim 7 , wherein the nanoparticle is PEGylated.
10. The method of claim 5 , wherein the siRNA is administered as a viral vector.
11. The method of claim 6 , wherein the shRNA is administered as a viral vector.
12. The method of claim 1 , wherein the cancer is an osteosarcoma.
13. The method of claim 1 , wherein the cancer is an anaplastic thyroid carcinoma.
14. The method of claim 1 , wherein the cancer is large cell lung cancer.
15. The method of claim 2 , wherein the fibrosis is in response to an injury.
16. The method of claim 2 , wherein the fibrosis is a fibroma, pulmonary fibrosis, cystic fibrosis, hepatic cirrhosis, endomyocardial fibrosis, from a previous myocardial infarction, atrial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis of the lungs, a complication of pneumoconiosis, nephrogenic systemic fibrosis, Crohn's disease fibrosis, keloid fibrosis, scleroderma/systemic sclerosis of skin or lungs, arthrofibrosis or adhesive capsulitis fibrosis.
17. The method of claim 2 , wherein the scarring is skin scarring, cardiovascular scarring, cardiac tissue scarring or neuronal scarring.
18. The method of claim 3 , wherein the wound is a skin wound, cardiovascular wound, cardiac tissue scarring or neuronal wound.